SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SABS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sabs · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
SAB Biotherapeutics, Inc.You SABS | $32M | N/A | — | — |
 AN2 Therapeutics, Inc. ANTX | $105M | N/A | — | -$1.16 |
 Boundless Bio, Inc. BOLD | $32M | N/A | — | -$2.60 |
 Evaxion Biotech A/S EVAX | $24M | N/A | — | -$1.20 |
 Generation Bio Co. GBIO | $36M | N/A | — | -$19.76 |
 Iterum Therapeutics plc ITRM | $2M | N/A | — | -$1.26 |
 Jasper Therapeutics, Inc. JSPR | $7M | N/A | — | -$3.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for SAB Biotherapeutics, Inc. (SABS) measures how much investors pay for each dollar of the company's trailing earnings. SABS's current PE ratio of N/A is calculated by dividing its stock price of $3.40 by its TTM earnings per share of —.
Frequently asked questions
SABS pe ratio · 6 questionsSABS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.40 and TTM EPS of —. Data sourced from Financial Modeling Prep via SABS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · SAB Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09